Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe

Recent 50 System Agreement with SimonMed Imaging Highlights Significant Value of ProFound AI Solution

Expert Panel Reviews Compelling Clinical Data on Xoft® Brain IOR... Continue reading

NASHUA, N.H., July 28, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2020, after the market close, and host a conference call at 4:30 pm Eastern Time on Tuesday, August 4.

Tuesday, August 4th @ 4:30pmET

Domestic:

877-407-0784

Continue reading

NASHUA, N.H. – July 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Jeffrey Sirek was appointed as Senior Vice President and General Manager of Xoft.

“We are very pleased to add Mr. Sirek to our Company. He brings to the team a proven track record of high sales productivity, brand development, marketing success, and revenue growth,” said Stacey Steve... Continue reading

First and only commercially available clinical decision support tool provides accurate two-year breast cancer risk estimation personalized for each woman

iCAD unveils new technology and clinical research at major medical conference

NAS... Continue reading

According to the International Agency for Research on Cancer, in 2018 breast cancer accounted for 26.4 percent of all new cancer cases in European women.[i] Europe’s radiologist shortage, particularly in Scotland and the United Kingdom, where the shortage is dire, makes it hard to maintain medical standards.[ii] Without a sufficient number of radiologists for 1st and 2nd reads, there’s a risk that abnormalities may be missed.

The close scrutiny radiologists give to each image takes time and can be visually and mentally e... Continue reading

Leading-edge artificial intelligence (AI) software allows patients to receive “real time” essential breast screening amidst pandemic

NASHUA, N.H. and PHOENIX– July 13, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and SimonMed Imaging, one of the largest outpatient medical imaging providers and largest physician radiology practice... Continue reading

Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives

Overall survival benefit reached statistical significance in the IORT group with tumors less than or equal to 2.5 cm3 (p<0.05)

Researchers recently presented positive new clinical data supporting the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of gliob... Continue reading

Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure

iCAD hosted a free virtual roundtable event for clinicians, titled “The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm PT. To view the webinar on-demand, please visit this link: https://www.icadmed.com/educational-webinars.html.

 Continue reading

 Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure

NASHUA, N.H. – June 1, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm PT. Event registration is availa... Continue reading

Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives

Overall survival benefit reached statistical significance in the IORT group with tumors less than or equal to 2.5 cm3 (p<0.05)

NASHUA, N.H. – May 13, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced... Continue reading

Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives

Conference Call Today at 4:30 p.m. ET

NASHUA, N.H. – MAY 11, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the first quarter ended March 31, 2020

Recent Highlights:

NASHUA, N.H. , May 05, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2020, after the market close, and host a conference call at 4:30 pm Eastern Time on Monday, May 11.

Monday, May 11th @ 4:30pmET

Domestic:

888-394-8218

International:<... Continue reading

Wooster Community Hospital Adopts ProFound AI for Digital Breast Tomosynthesis to Optimize Breast Cancer Screening and Improve Workflow

iCAD’s educational webinar series recently featured Gabriele Pedicelli, MD, Radiologist at Wooster Community Hospital, who shared how ProFound AI™ not only improved workflow at his facility, it also resulted in a positive impact on his practice’s bottom line. Learn how this leading-edge AI tool empowered Dr. Pedicelli and his team to increase... Continue reading

NASHUA, N.H., April 23, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (Nasdaq: ICAD) today announced it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,562,500  shares of the Company’s common stock at .00 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately .5 million before deducting estimated offering expenses. The Company intends to use the net proceeds for working capital and for other general corporate purposes, including for the conduct... Continue reading

Educational awareness forum to feature leading experts in discussions on risk adaptive tools and pragmatic solutions to enhance patient care during COVID-19 pandemic

Event kicks off series of informational webinars featuring breast cancer thought leaders sharing best practices using leading-edge technologies in cancer detection and treatment

Educational awareness forum to feature leading experts in discussions on risk adaptive tools and pragmatic solutions to enhance patient care during COVID-19 pandemic

Event kicks off series of informational webinars featuring breast cancer thought leaders sharing best practices using leading-edge technologies in cancer detection and treatment<... Continue reading

NASHUA, N.H. – March 31, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it has entered into a credit facility with Bridge Bank, a division of Western Alliance Bank, effective March 30, 2020.

The new credit facility consists of a million term loan and a million revolving line of credit. The four-year term loan will be interest-only for the first 18 months, which could be extended by an additional six month... Continue reading

In recent weeks, the number of people diagnosed with the coronavirus, or COVID-19, has rapidly increased, impacting our lives in unprecedented ways and placing a growing burden upon hospitals and clinicians worldwide. This emerging issue has led organizations such as the American College of Radiology, the American Cancer Society, and Susan G. Komen to advise lower-risk women to consider rescheduling routine mammograms so hospitals may address critical COVID-19 cases. [i],[ii],[iii] However, this guidance may be confusing to both women and clinicians, and... Continue reading

ProFound AI can assist radiologists in prioritizing patients for breast cancer screening and address the growing mammography backlog

Xoft breast IORT offers single-fraction therapy alternative to weeks of daily radiation, reducing resources needed and minimizing patients’ risk of COVID-19 exposure

ProFound AI can assist radiologists in prioritizing patients for breast cancer screening and address the growing mammography backlog

Xoft breast IORT offers single-fraction therapy alternative to weeks of daily radiation, reducing resources needed and minimizing patients’ risk of COVID-19 exposure

Continue reading